Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00160732 · ClinicalTrials.gov registry record · Phase 1

Allogenic Islet Cell Transplantation

A Phase 1 study of Diabetes Mellitus, Type 1, sponsored by University of Chicago.

Active
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT00160732: Active Phase 1 study of Diabetes Mellitus, Type 1, sponsored by University of Chicago.

NCT00160732 is a Phase 1 study of Diabetes Mellitus, Type 1 that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 50 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00160732, a Phase 1 study of Diabetes Mellitus, Type 1, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle and/or complex patients with type 1 diabetes. In addition, initial observations will be made with regards to the effectiveness of reversing hypoglycemia with this treatment. The "Edmonton Protocol" of using specific anti-rejection drugs without steroids is also being evaluated.

Conditions Studied

Diabetes Mellitus, Type 1

Interventions

  • PROCEDURE Intraportal infusion of islet cells
  • DRUG Allogenic islet cells (human, U. Chicago)

Study Locations (1)

Illinois

  • The University of Chicago Hospitals - Chicago

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2003-10
Est. Completion 2030-10
Phase Phase 1
University of Chicago

796 total trials

What the registry record for NCT00160732 still lists

NCT00160732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Intraportal infusion of islet cells is the first listed.

NCT00160732 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00160732 about?

NCT00160732 is a clinical study titled "Allogenic Islet Cell Transplantation". The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle and/or complex patients with type 1 diabetes. In addition, initial observations will be made with regards to the effectiveness of reversing hypoglycemia with this treatmen...

What is the current status of trial NCT00160732?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2003-10. Estimated completion is 2030-10.

What conditions does trial NCT00160732 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT00160732?

The interventions under investigation include: Intraportal infusion of islet cells (PROCEDURE), Allogenic islet cells (human, U. Chicago) (DRUG).

Who is sponsoring clinical trial NCT00160732?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00160732 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00160732's enrollment target sits among peer trials

50 70th of 118 higher than 44 of 118 other Diabetes Mellitus, Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00160732, the US trial registry maintained by the National Library of Medicine. NCT00160732 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.